Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug-resistant Acinetobacter baumannii Infections - A Systematic Review.
Hemasri VelmuruganSajitha VenkatesanHadush Negash MelesPugazhenthan ThangarajuKrishnapriya NeelambaramPublished in: Infectious disorders drug targets (2024)
The findings from the studies show that SUL-DUR might be a successful therapeutic option for multidrug-resistant-Ab infections. Future clinical trials will be required to validate the possibility of using this combination to treat multidrug-resistant A. baumannii infections.
Keyphrases
- multidrug resistant
- acinetobacter baumannii
- drug resistant
- gram negative
- clinical trial
- klebsiella pneumoniae
- pseudomonas aeruginosa
- emergency department
- randomized controlled trial
- escherichia coli
- current status
- replacement therapy
- combination therapy
- adverse drug
- case control
- electronic health record
- smoking cessation